Table 1 Biochemical and anthropometric characteristics of patients with type 2 diabetes mellitus
Variables | T2DM N = 529 |
|---|---|
Age (years) | 67 (62–72) |
Sex (Males, %) | 280 (53%) |
Current smoking (n, %) | 78 (15%) |
BMI (Kg/m2) | 28.1 (25.8–31.4) |
Weight (Kg) | 77 (69–86) |
Waist-hip ratio | 0.94 (0.89–0.98) |
Total cholesterol (mg/dL) | 204 (181–233) |
LDL-C (mg/dL) | 114 (96–136) |
HDL-C (mg/dL) | 50 (42–60) |
non-HDL-C (mg/dl) | 152 (130–177) |
Triglycerides (mg/dL) | 115 (83–159) |
Remnant cholesterol (mg/dL) | 34 (23–50) |
ApoB (mg/dL) | 100 (84–118) |
ApoA1 (mg/dL) | 164 (146–186) |
PCSK9 (ng/mL) | 260 (211–305) |
Fasting glucose (mg/dL) | 153 (133–183) |
HbA1C (%) | 7.3 (6.6–8.0) |
Insulin (µUI/mL) | 5.69 (3.66–8.62) |
HOMA index | 2.14 (1.39–3.56) |
Hemoglobin (g/dL) | 14.2 (13.4–15.2) |
WBC (n/mm3) | 6.57 (5.50–7.54) |
Platelets (n/mm3) | 209 (179–252) |
hs-CRP (mg/L) | 2.51 (1.23–4.65) |
Fibrinogen (mg/dL) | 298 (255–344) |
Iron (µg/dL) | 81 (64–96) |
Ferritin (ng/mL) | 88 (46–160) |
Creatinine (mg/dL) | 0.90 (0.70–1.00) |
eGFR (mL/min) | 81 (66–86) |
Azotemia (mg/dL) | 38 (32–46) |
Uric acid (mg/dL) | 4.6 (4.1–5.4) |
Alanine aminotransferase (U/L) | 39 (33–47) |
Aspartate aminotransferase (U/L) | 20 (16–24) |
Total bilirubin (mg/dL) | 0.6 (0.5–0.8) |
Gamma-glutamyl transferase (U/L) | 49 (39–61) |
Disease duration (years) | 14 (7–23) |
Relevant medications (n, %) | |
Any T2DM medication | 403 (76%) |
Metformin | 196 (37%) |
Sulphonylureas | 257 (49%) |
Glinides | 12 (2%) |
Insulin | 95 (18%) |
Statins | 103 (19%) |
Vitamin K antagonists | 52 (10%) |
T2DM complications (n, %) | |
Retinopathy | 149 (28%) |
Nephropathy | 68 (13%) |
Neuropathy | 98 (19%) |
History of MACE | 79 (15%) |
Peripheral artery disease | 50 (9%) |